Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma

References

• Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, Maskell NA, Psallidas I. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev. 2016;25(142):472–86. doi:10.1183/16000617.0063-2016.
   PubMed Web of Science ®Google Scholar
• Cavone D, Caputi A, De Maria L, Cannone ESS, Mansi F, Birtolo F, Delfino MC, Vimercati L. Epidemiology of mesothelioma. Enviroments. 2019;6(7):76. doi:10.3390/enviroments6070076.
   Web of Science ®Google Scholar
• RARECARENet. [ accessedMar 15]. http://rarecarenet.istitutotumori.mi.it/fact_sheets.php.
   Google Scholar
• National Cancer Institute – Surveillance, Epidemiology and End Results Program. [ accessed Mar 15]. https://seer.cancer.gov/csr/1975_2017/results_merged/sect_17_mesothelioma.pdf.
   Google Scholar
• Billé A, Krug LM, Woo KM, Rusch VW, Zauderer MG. Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol. 2016;11(2):249–55. doi:10.1016/j.jtho.2015.10.003.
   PubMed Web of Science ®Google Scholar
• Verma V, Ahern CA, Berlind CG, Lindsay WD, Shabason J, Sharma S, Culligan MJ, Grover S, Friedberg JS, Simone CB 2nd. Survival by histologic subtype of malignant pleural mesothelioma and the impact of surgical resection on overall survival. Clin Lung Cancer. 2018 2;19(5):e685–e692. doi:10.1016/j.cllc.2018.08.007.
   PubMed Web of Science ®Google Scholar
• Taioli E, Wolf AS, Camacho-Rivera M, Kaufman A, Lee DS, Nicastri D, Rosenzweig K, Flores RM. Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients. PLoS One. 2015;10(12):e0145039. doi:10.1371/journal.pone.0145039.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Malignant pleural mesothelioma. Version 1.2021. [accessed 2021 Jan 15]. https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf.
   Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44. doi:10.1200/JCO.2003.11.136.
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006;24(9):1443–48. doi:10.1200/JCO.2005.04.3190.
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Castagneto B, Zucali PA, Favaretto A, Mencoboni M, Grossi F, Cortinovis D, Del Conte G, Ceribelli A, Bearz A, et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer. 2008;99(1):51–56. doi:10.1038/sj.bjc.6604442.
   PubMed Web of Science ®Google Scholar
• Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008;19(2):370–73. doi:10.1093/annonc/mdm501.
   PubMed Web of Science ®Google Scholar
• Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–14. doi:10.1016/S0140-6736(15)01238-6.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, Jones CM, Miettinen M, Pass H, Rimner A, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(13):1343–73. doi:10.1200/JCO.2017.76.6394.
   PubMed Web of Science ®Google Scholar
• Ujiie H, Kadota K, Nitadori JI, Aerts JG, Woo KM, Sima CS, Travis WD, Jones DR, Krug LM, Adusumilli PS. The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers. Oncoimmunology. 2015;4(6):e1009285. doi:10.1080/2162402X.2015.1009285.
   PubMed Web of Science ®Google Scholar
• Chee SJ, Lopez M, Mellows T, Gankande S, Moutasim KA, Harris S, Clarke J, Vijayanand P, Thomas GJ, Ottensmeier CH. Evaluating the effect of immune cells on the outcome of patients with mesothelioma. Br J Cancer. 2017;117(9):1341–48. doi:10.1038/bjc.2017.269.
   PubMed Web of Science ®Google Scholar
• Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, et al. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. Ann Oncol. 2018;29(5):1258–65. doi:10.1093/annonc/mdy086.
   PubMed Web of Science ®Google Scholar
• Salaroglio IC, Kopecka J, Napoli F, Pradotto M, Maletta F, Costardi L, Gagliasso M, Milosevic V, Ananthanarayanan P, Bironzo P, et al. Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma. J Thorac Oncol. 2019;14(8):1458–71. doi:10.1016/j.jtho.2019.03.029.
   PubMed Web of Science ®Google Scholar
• Chéné AL, d’Almeida S, Blondy T, Tabiasco J, Deshayes S, Fonteneau JF, Cellerin L, Delneste Y, Grégoire M, Blanquart C. Pleural effusions from patients with mesothelioma induce recruitment of monocytes and their differentiation into M2 macrophages. J Thorac Oncol. 2016;11(10):1765–73. doi:10.1016/j.jtho.2016.06.022.
   PubMed Web of Science ®Google Scholar
• Marcq E, Waele J, Audenaerde JV, Lion E, Santermans E, Hens N, Pauwels P, van Meerbeeck JP, Smits ELJ. Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients. Oncotarget. 2017;8(52):89722–35. doi:10.18632/oncotarget.21113.
   PubMedGoogle Scholar
• Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014;9(7):1036–40. doi:10.1097/jto.0000000000000177.
   PubMed Web of Science ®Google Scholar
• Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One. 2015;10(3):e0121071. doi:10.1371/journal.pone.012107.
   PubMed Web of Science ®Google Scholar
• Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Hum Pathol. 2016;52:9–18. doi:10.1016/j.humpath.2016.01.010.
   PubMed Web of Science ®Google Scholar
• Thapa B, Salcedo A, Lin X, Walkiewicz M, Murone C, Ameratunga M, Asadi K, Deb S, Barnett SA, Knight S, et al. The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma. J Thorac Oncol. 2017 May;12(5):850–59. doi:10.1016/j.jtho.2017.02.013.
   PubMed Web of Science ®Google Scholar
• Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, et al. Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the Bio-MAPS cohort. Clin Lung Cancer. 2019;20(5):e564–e575. doi:10.1016/j.cllc.2019.04.010.
   PubMed Web of Science ®Google Scholar
• Awad MM, Jones RE, Liu H, Lizotte PH, Ivanova EV, Kulkarni M, Herter-Sprie GS, Liao X, Santos AA, Bittinger MA, et al. Cytotoxic T cells in PD-L1-positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors. Cancer Immunol Res. 2016;4:1038–48. doi:10.1158/2326-6066.CIR-16-0171.
   PubMed Web of Science ®Google Scholar
• Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20(11):1425–34. doi:10.1038/s41590-019-0512-0.
   PubMed Web of Science ®Google Scholar
• Klampatsa A, O’Brien SM, Thompson JC, Rao AS, Stadanlick JE, Martinez M, Liousia M, Cantu E, Cengel K, Moon EK, et al. Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes. Oncoimmunology. 2019;8:e1638211. doi:10.1080/2162402X.2019.1638211.
   PubMed Web of Science ®Google Scholar
• Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407–16. doi:10.1038/ng.3520.
   PubMed Web of Science ®Google Scholar
• Arulananda S, Thapa B, Walkiewicz M, Zapparoli GV, Williams DS, Dobrovic A, John T. Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma. J Thorac Oncol. 2018;13(10):1588–94. doi:10.1016/j.jtho.2018.07.015.
   PubMed Web of Science ®Google Scholar
• Losi L, Bertolini F, Guaitoli G, Fabbiani L, Banchelli F, Ambrosini-Spaltro A, Botticelli L, Scurani L, Baldessari C, Barbieri F, et al. Role of evaluating tumor-infiltrating lymphocytes, programmed death-1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma. Int J Oncol. 2019;55(5):1157–64. doi:10.3892/ijo.2019.4883.
   PubMed Web of Science ®Google Scholar
• Yoshikawa Y, Emi M, Hashimoto-Tamaoki T, Ohmuraya M, Sato A, Tsujimura T, Hasegawa S, Nakano T, Nasu M, Pastorino S, et al. High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proc Natl Acad Sci USA. 2016;113(47):13432–37. doi:10.1073/pnas.1612074113.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Peikert T, Vasmatzis G. Chromosomal rearrangements and their neoantigenic potential in mesothelioma. Transl Lung Cancer Res. 2020;9(Suppl 1):S92–S99. doi:10.21037/tlcr.2019.11.12.
   PubMed Web of Science ®Google Scholar
• Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ, Santoro A. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer. 2008;112(7):1555–61. doi:10.1002/cncr.23337.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennel D, Steeke JPC. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009;63(1):94–97. doi:10.1016/j.lungcan.2008.04.001.
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer. 2011;72(1):73–77. doi:10.1016/j.lungcan.2010.12.004.
   PubMed Web of Science ®Google Scholar
• Sørensen J, Urbanska E, Langer S, Aamdal E. Second-line oral vinorelbine following first-line platinum and pemetrexed in malignant pleural mesothelioma. Eur J Clin Med Oncol. 2012;4:1–7.
   Google Scholar
• Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R, Giordano L, Santoro A. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer. 2014;84(3):265–70. doi:10.1016/j.lungcan.2013.11.011.
   PubMed Web of Science ®Google Scholar
• Gregorc V, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, et al. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2018;19(6):799–811. doi:10.1016/s1470-2045(18)30193-1.
   PubMed Web of Science ®Google Scholar
• Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O’Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European thoracic oncology platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol. 2020;31(12):1734–45. doi:10.1016/j.annonc.2020.09.009.
   PubMed Web of Science ®Google Scholar
• Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14(11):1104–11. doi:10.1016/s1470-2045(13)70381-4.
   PubMed Web of Science ®Google Scholar
• Calabrò L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015;3(4):301–09. doi:10.1016/S2213-2600(15)00092-2.
   PubMed Web of Science ®Google Scholar
• Maio M, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennel DA, Kowalski D, Tsao AS, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261–73. doi:10.1016/S1470-2045(17)30446-1.
   PubMed Web of Science ®Google Scholar
• Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lelezari F, Thunnissen E, Monkhorst K, Schouten R, Schunselaar DM, Disselhorst M, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13(10):1569–76. doi:10.1016/j.jtho.2018.05.038.
   PubMed Web of Science ®Google Scholar
• Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). Clin Cancer Res. 2019;25(18):5485–92. doi:10.1158/1078-0432.ccr-19-0103.
   PubMed Web of Science ®Google Scholar
• Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239–53. doi:10.1016/s1470-2045(18)30765-4.
   PubMed Web of Science ®Google Scholar
• Fennell D, Ottensmeier C, Califano R, Hanna GG, Ewings S, Kayleigh H, Wilding S, Danson S, Nye M, Steele N, et al. Nivolumab versus placebo in relapsed malignant mesothelioma: preliminary results from the CONFIRM phase 3 trial. Presented at: International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer; 2021 Jan 28–31. Singapore: Virtual. Abstract PS01.11.
   Google Scholar
• Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):623–30. doi:10.1016/S1470-2045(17)30169-9.
   PubMed Web of Science ®Google Scholar
• Desai A, Karrison T, Rose B, Tan Y, Hill B, Pemberton E, Straus C, Seiwert T, Kindler HL. Phase II Trial of pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): final analysis. J Thorac Oncol. 2018;13(10):S339. (abstract). doi:10.1016/j.jtho.2018.08.277.
   Web of Science ®Google Scholar
• Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, et al. Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. J Thorac Oncol. 2018;13(11):1784–91. doi:10.1016/j.jtho.2018.08.007.
   PubMed Web of Science ®Google Scholar
• Rivalland G, Kao SC-H, Pavlakis N, Gordon B, Hughes M, Thapa B, Pal A, Walkiewicz M, Zimet AS, White S, et al. Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression. J Clin Oncol. 2017;35(15suppl):8514. (abstract). doi:10.1200/JCO.2017.35.15_suppl.8514Rivalland G, Kao SC-H, Pavlakis N, Gordon B, Hughes M, Thapa B, Pal A, Walkiewicz M, Zimet AS, White S, et al. Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression. J Clin Oncol. 2017;35(15suppl):8514. (abstract). doi:10.1200/JCO.2017.35.15_suppl.8514.Rivalland G, Kao SC-H, Pavlakis N, Gordon B, Hughes M, Thapa B, Pal A, Walkiewicz M, Zimet AS, White S, et al. Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression. J Clin Oncol. 2017;35(15suppl):8514. (abstract). doi:10.1200/JCO.2017.35.15_suppl.8514.
   Web of Science ®Google Scholar
• Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen FL, Delord JP, Dowlati A, Kochuparambil ST, Taylor MH, et al. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2019;5(3):351–57. doi:10.1001/jamaoncol.2018.5428.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–31. doi:10.1056/NEJMoa1910231.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90. doi:10.1056/NEJMoa1712126.
   PubMed Web of Science ®Google Scholar
• Calabrò L, Morra A, Giannarelli D, Amato G, D’Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R, Altomonte M, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018;6(6):451–60. doi:10.1016/S2213-2600(18)30151-6.
   PubMed Web of Science ®Google Scholar
• Venkatraman D, Anderson A, Digumarthy S, Lizotte PH, Awad MM. Phase 2 study of tremelimumab plus durvalumab for previously-treated malignant pleural mesothelioma (MPM). J Clin Oncol. 2019;37(15suppl):8549. (abstract). doi:10.1200/JCO.2019.37.15_suppl.8549.
   Google Scholar
• Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF, van der Noort V, Harms E, Burgers S, Baas P. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7(3):260–70. doi:10.1016/S2213-2600(18)30420-X.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Lesterhuis WJ, Kok PS, Brown C, Hughes BG, Karikios DJ, John T, Kao SC, Leslie C, Cook AM, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020;21(9):1213–23. doi:10.1016/S1470-2045(20)30462-9.
   PubMed Web of Science ®Google Scholar
• Forde PM, Sun Z, Anagnostou V, Kindler HL, Purcell WT, Goulart BHL, Dudek AZ, Borghaei H, Brahmer JR, Ramalingam SS. PrE0505: phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM) — a PrECOG LLC study. J Clin Oncol. 2020;38(suppl):9003. (abstract). doi:10.1200/JCO.2020.38.15_suppl.9003.
   Google Scholar
• Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021 Jan 30;397(10272):375–86. doi:10.1016/S0140-6736(20)32714-8.
   PubMed Web of Science ®Google Scholar
• Lantuejoul S, Le Stang N, Damiola F, Scherpereel A, Galateau-Sallé F. PD-L1 testing for immune checkpoint inhibitors in mesothelioma: for want of anything better? J Thorac Oncol. 2017;12(5):778–81. doi:10.1016/j.jtho.2017.03.018.
   PubMed Web of Science ®Google Scholar